New York State Common Retirement Fund buys 1,637 shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)


New York State Common Retirement Fund increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ: RAREGet a rating) by 0.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 185,040 shares of the biopharmaceutical company after acquiring an additional 1,637 shares during the period. The New York State Common Retirement Fund held 0.27% of Ultragenyx Pharmaceutical worth $13,438,000 at the end of the most recent reporting period.

Other hedge funds have also increased or reduced their stakes in the company. Victory Capital Management Inc. increased its stake in Ultragenyx Pharmaceutical by 12.4% in Q4. Victory Capital Management Inc. now owns 7,438 shares of the biopharmaceutical company worth $625,000 after acquiring 823 additional shares last quarter. The State Board of Administration of Florida Retirement System increased its stake in Ultragenyx Pharmaceutical by 0.5% in Q4. The Florida Retirement System State Board of Directors now owns 86,652 shares of the biopharmaceutical company worth $7,287,000 after acquiring 439 additional shares last quarter. Advisor Group Holdings Inc. increased its stake in Ultragenyx Pharmaceutical by 75.6% in Q4. Advisor Group Holdings Inc. now owns 2,830 shares of the biopharmaceutical company worth $236,000 after acquiring 1,218 additional shares in the last quarter. Alliancebernstein LP increased its stake in Ultragenyx Pharmaceutical by 13.1% in the 4th quarter. Alliancebernstein LP now owns 1,308,156 shares of the biopharmaceutical company worth $110,003,000 after acquiring an additional 152,002 shares last quarter. Finally, Virginia Retirement Systems ET AL increased its stake in shares of Ultragenyx Pharmaceutical by 13.0% during the fourth quarter. Virginia Retirement Systems ET AL now owns 13,900 shares of the biopharmaceutical company valued at $1,169,000 after buying an additional 1,600 shares last quarter. 97.49% of the shares are currently held by institutional investors.

Ultragenyx pharmaceutical stock down 0.3%

Shares of NASDAQ RARE opened at $55.60 on Friday. The company’s 50-day simple moving average is $55.66 and its 200-day simple moving average is $63.38. The company has a market capitalization of $3.89 billion, a price-earnings ratio of -7.60 and a beta of 1.21. Ultragenyx Pharmaceutical Inc. has a 52-week low of $45.20 and a 52-week high of $104.38.

Pharmaceutical Ultragenyx (NASDAQ: RAREGet a rating) last released its quarterly results on Thursday, July 28. The biopharmaceutical company reported ($2.26) earnings per share for the quarter, missing the consensus estimate of ($1.72) by ($0.54). The company posted revenue of $89.34 million in the quarter, compared to $87.33 million expected by analysts. Ultragenyx Pharmaceutical posted a negative return on equity of 60.76% and a negative net margin of 151.34%. The company’s quarterly revenue increased 2.7% year over year. In the same period a year earlier, the company posted ($1.45) earnings per share. Equity research analysts expect Ultranyx Pharmaceutical Inc. to post EPS of -7.79 for the current fiscal year.

Wall Street analysts predict growth

RARE has been the subject of a number of recent research reports. Goldman Sachs Group lowered its price target on shares of Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a “neutral” rating on the stock in a Tuesday, May 24 research note. Cowen cut his price target on shares of Ultragenyx Pharmaceutical from $124.00 to $99.00 in a Friday, May 6 research report. Citigroup lowered its price target on shares of Ultragenyx Pharmaceutical from $146.00 to $142.00 in a report on Wednesday. Cowen cut his price target on shares of Ultragenyx Pharmaceutical from $124.00 to $99.00 in a Friday, May 6 report. Finally, Barclays cut its price target on shares of Ultragenyx Pharmaceutical from $141.00 to $105.00 in a Friday July 29 report. Two equity research analysts rated the stock with a sell rating, one gave the company a hold rating and seven gave the company a buy rating. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $112.67.

About Ultranyx Pharmaceutical

(Get a rating)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Further reading

Institutional ownership by quarter for Ultragenyx Pharmaceutical (NASDAQ: RARE)



Get news and reviews for Ultragenyx Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.